ChemoCentryx Inc. (NASDAQ:CCXI) insider Petrus Bekker sold 33,332 shares of the stock in a transaction that occurred on Friday, November 11th. The shares were sold at an average price of $8.00, for a total value of $266,656.00. Following the completion of the sale, the insider now directly owns 54,228 shares of the company’s stock, valued at approximately $433,824. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink.

Shares of ChemoCentryx Inc. (NASDAQ:CCXI) opened at 7.78 on Wednesday. ChemoCentryx Inc. has a one year low of $1.92 and a one year high of $8.30. The firm’s market cap is $371.92 million. The firm’s 50-day moving average price is $6.35 and its 200 day moving average price is $4.99.

Insider Buying and Selling by Quarter for ChemoCentryx (NASDAQ:CCXI)

Separately, JPMorgan Chase & Co. reissued a “buy” rating and issued a $11.00 price objective on shares of ChemoCentryx in a report on Tuesday, August 9th.

A number of large investors have recently modified their holdings of CCXI. Connor Clark & Lunn Investment Management Ltd. acquired a new stake in shares of ChemoCentryx during the third quarter worth $167,000. Nantahala Capital Management LLC increased its stake in ChemoCentryx by 8.8% in the third quarter. Nantahala Capital Management LLC now owns 466,440 shares of the biopharmaceutical company’s stock valued at $2,817,000 after buying an additional 37,753 shares in the last quarter. Baker BROS. Advisors LP purchased a new stake in ChemoCentryx during the third quarter valued at approximately $296,000. KCG Holdings Inc. purchased a new stake in ChemoCentryx during the third quarter valued at approximately $126,000. Finally, Acrospire Investment Management LLC increased its stake in ChemoCentryx by 192.9% in the third quarter. Acrospire Investment Management LLC now owns 31,040 shares of the biopharmaceutical company’s stock valued at $187,000 after buying an additional 20,441 shares in the last quarter. Institutional investors and hedge funds own 48.01% of the company’s stock.

About ChemoCentryx

ChemoCentryx, Inc (ChemoCentryx) is a biopharmaceutical company. The Company is focused on discovering, developing and commercializing orally-administered therapeutics to treat orphan and rare diseases, autoimmune diseases, inflammatory disorders and cancer. It targets the chemoattractant system, which is a network of molecules, including chemokine ligands and their associated receptors, as well as related chemoattractant receptors.

5 Day Chart for NASDAQ:CCXI

Receive News & Stock Ratings for ChemoCentryx Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ChemoCentryx Inc. and related stocks with our FREE daily email newsletter.